Poor
Not Aligned
Patient Risk:
High
Summary
Several high-impact labeling-adherence errors are present: the response incorrectly describes as-needed acute migraine attack prevention and incorrectly states healthcare professional-only administration. These directly conflict with labeled preventive, fixed once-monthly dosing and intended patient self-administration.
Category Scores
Accurate Statements
Aimovig is a prescription medication used to treat adult patients with migraine.
1 INDICATIONS AND USAGE: "AIMOVIG is indicated for the preventive treatment of migraine in adults."
Aimovig is administered via a monthly injection of 70 milligrams or 140 milligrams into the skin.
2.1 Recommended Dosing: "70 mg injected subcutaneously once monthly" and "140 mg injected subcutaneously once monthly."
The recommended dosage of Aimovig is one injection per month.
2.1 Recommended Dosing: "once monthly" for both 70 mg and 140 mg.
Unsupported Statements
Aimovig is administered on the same day each month.
Label section provided does not explicitly state "same day each month"; it discusses missed-dose administration and scheduling from the date of the last dose.
For maintenance therapy, a single 140-milligram injection of Aimovig is administered once a month.
Label provided supports 140 mg once monthly but does not use the term "maintenance therapy."
Contradictions
High
AI Statement
Aimovig may be administered as-needed for acute migraine attack prevention for patients who experience headache days on which they require treatment.
Label Reference
1 INDICATIONS AND USAGE (preventive treatment) and 2.1 Recommended Dosing (once-monthly dosing).
Moderate
AI Statement
Aimovig injections should be administered by a healthcare professional.
Label Reference
2.2 Important Administration Instructions: "AIMOVIG is intended for patient self-administration."
Important Omissions
No dosing-with-missed-dose instruction included (e.g., administer as soon as possible after a missed dose and then schedule monthly from the date of the last dose).
Importance:
Moderate
Key administration constraints for subcutaneous use only (not provided as such in the extracted claims).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Contradicted claims include incorrect as-needed acute-use framing versus labeled preventive once-monthly dosing, and incorrect administration setting (healthcare professional-only) versus intended patient self-administration.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Two label-critical contradictions: (1) as-needed acute migraine attack prevention instead of preventive fixed once-monthly dosing; (2) healthcare professional-only administration despite labeled patient self-administration.
Suggested Improvement
Remove as-needed/acute-prevention wording and align to labeled preventive indication and once-monthly subcutaneous dosing; correct administration to reflect intended patient self-administration and ensure subcutaneous-only routing and labeled injection site wording.